Post Marketing Study of Stronger Neo Minophagen C for Elderly Patients of Chronic Hepatitis C -Prospective Study-

Post Marketing Study of Stronger Neo Minophagen C for Elderly Patients of Chronic Hepatitis C -Prospective Study- - Post Marketing Study of Stronger Neo Minophagen C for Elderly Patients of Chronic Hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014234

Enrollment

1500

Registered

2014-06-11

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C Cirrhosis Hepatoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis C patients with alanine aminotransferase (ALT) 31IU/L or higher who could not receive antiviral therapy 70 years or older at the time of registration, and intended to undergo treatment for at least one year

Exclusion criteria

Exclusion criteria: Contraindication(s) for SNMC treatment Presence of hepatitis B Being deemed otherwise unsuitable by the physicians conducting the study.

Design outcomes

Primary

Measure	Time frame
It thus set out to investigate the efficacy and safety of SNMC for 70 years or older chronic hepatitis C patients and therefore generally unable to receive antiviral therapy.	—

Countries

Japan

Contacts

Public ContactKunio Okuni

Minophagen Pharmaceutical Co.,Ltd Medical Information Department

k_ookuni@minophagen.co.jp03-5909-0033

Outcome results